Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (421-430 of 520) with videos related to

Pageof 52
Sort By:
Journal of Diabetes Research|January 17, 2019
Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease DurationJelena P Seferovic, Rhonda Bentley-Lewis, Brian Claggett, et al.
European Journal of Heart Failure|November 17, 2022
Health-related quality of life outcomes in PARAGON-HFAlvin Chandra, Carisi A Polanczyk, Brian L Claggett, et al.
European Heart Journal|June 26, 2023
Stroke in patients with heart failure and reduced or preserved ejection fractionMingming Yang, Toru Kondo, Jawad H Butt, et al.
European Heart Journal|May 28, 2026
Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysisRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Journal of the American College of Cardiology|January 2, 2025
Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 TrialsHenri Lu, Toru Kondo, Brian L Claggett, et al.
JACC. Heart Failure|November 21, 2024
Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF TrialFinnian R Mc Causland, Muthiah Vaduganathan, Brian Claggett, et al.
Circulation. Heart Failure|October 22, 2021
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection FractionMasatoshi Minamisawa, Brian Claggett, Kota Suzuki, et al.
Annals of Internal Medicine|April 2, 2003
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathyTomas Berl, Lawrence G Hunsicker, Julia B Lewis, et al.
European Journal of Heart Failure|January 6, 2022
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failureFinnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
Circulation|August 27, 2020
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection FractionFinnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
Pageof 52

Showing results (421-430 of 520) with videos related to

Sort By:
Pageof 52
Journal of Diabetes Research|January 17, 2019
Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease DurationJelena P Seferovic, Rhonda Bentley-Lewis, Brian Claggett, et al.
European Journal of Heart Failure|November 17, 2022
Health-related quality of life outcomes in PARAGON-HFAlvin Chandra, Carisi A Polanczyk, Brian L Claggett, et al.
European Heart Journal|June 26, 2023
Stroke in patients with heart failure and reduced or preserved ejection fractionMingming Yang, Toru Kondo, Jawad H Butt, et al.
European Heart Journal|May 28, 2026
Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysisRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Journal of the American College of Cardiology|January 2, 2025
Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 TrialsHenri Lu, Toru Kondo, Brian L Claggett, et al.
JACC. Heart Failure|November 21, 2024
Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF TrialFinnian R Mc Causland, Muthiah Vaduganathan, Brian Claggett, et al.
Circulation. Heart Failure|October 22, 2021
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection FractionMasatoshi Minamisawa, Brian Claggett, Kota Suzuki, et al.
Annals of Internal Medicine|April 2, 2003
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathyTomas Berl, Lawrence G Hunsicker, Julia B Lewis, et al.
European Journal of Heart Failure|January 6, 2022
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failureFinnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
Circulation|August 27, 2020
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection FractionFinnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
Pageof 52